跳转至内容
Merck

SHC005V

Sigma-Aldrich

MISSION® eGFP Control Transduction Particles

shRNA sequence targeting eGFP

别名:

MISSION®

登录查看公司和协议定价


About This Item

分類程式碼代碼:
41106609
NACRES:
NA.51

產品線

MISSION®

濃度

≥1x106 VP/ml (via p24 assay)

技術

capture ELISA: 106 TU/mL using p24

運輸包裝

dry ice

儲存溫度

−70°C

正在寻找类似产品? 访问 产品对比指南

一般說明

The MISSION eGFP shRNA Control Transduction Particles contain an shRNA sequence targeting eGFP (GenBank Accession No. pEGFP U55761). The eGFP shRNA Control Particles are useful as a positive knockdown control in experiments using cell lines expressing eGFP.
The eGFP shRNA Control Transduction Particles are produced from the sequence-verified lentiviral plasmid, pLKO.1-puro-eGFP shRNA (Prod. No. SHC005). Self-inactivating replication incompetent viral particles are produced in packaging cells (HEK293T) by co-transfection with compatible packaging plasmids. In addition, the control transduction particles are pseudotyped with an envelope G glycoprotein from Vesicular Stomatitis Virus (VSV-G), allowing transduction of a wide variety of mammalian cells. 200 μl of 106 TU/ml (via p24 titering assay) lentiviral particles are provided as frozen stock.
当使用MISSION® TRC shRNA克隆进行实验时,选择适当对照品是您的实验设计的关键要素,以便准确解释敲低结果。 MISSION对照转导颗粒是监测转导效率的关键阳性对照。
想要查看更多应用数据、实验方案和载体图谱,请访问 sigma.com/shrna

應用

To see more application data, protocols, vector maps visit sigma.com/shrna.

法律資訊

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable

個人防護裝備

Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Marine Warnier et al.
Aging cell, 17(3), e12736-e12736 (2018-02-16)
Oncogenic signals lead to premature senescence in normal human cells causing a proliferation arrest and the elimination of these defective cells by immune cells. Oncogene-induced senescence (OIS) prevents aberrant cell division and tumor initiation. In order to identify new regulators
Mariano J Alvarez et al.
Nature genetics, 50(7), 979-989 (2018-06-20)
We introduce and validate a new precision oncology framework for the systematic prioritization of drugs targeting mechanistic tumor dependencies in individual patients. Compounds are prioritized on the basis of their ability to invert the concerted activity of master regulator proteins
R Zufferey et al.
Journal of virology, 72(12), 9873-9880 (1998-11-13)
In vivo transduction of nondividing cells by human immunodeficiency virus type 1 (HIV-1)-based vectors results in transgene expression that is stable over several months. However, the use of HIV-1 vectors raises concerns about their safety. Here we describe a self-inactivating
Cell-cycle dependent expression of a translocation-mediated fusion oncogene mediates checkpoint adaptation in rhabdomyosarcoma.
Kikuchi K, Hettmer S, Aslam MI, et al.
PLoS Genetics, 10(1), e1004107-e1004107 (2014)
Ruth S Cruz Cosme et al.
Journal of virology, 83(7), 2839-2850 (2009-01-16)
Human cytomegalovirus (HCMV), a member of the beta subgroup of the family Herpesviridae, causes serious health problems worldwide. HCMV gene expression in host cells is a well-defined sequential process: immediate-early (IE) gene expression, early-gene expression, DNA replication, and late-gene expression.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门